CoChat

Mutant ATRX: uncovering a new therapeutic target for glioma

Open access
Haase, Santiago, Garcia-Fabiani, María Belén, Carney, Stephen, Altshuler, David, Núñez, Felipe J., Méndez, Flor M., Núñez, Fernando, Lowenstein, Pedro R., Castro, Maria G. · 2018 · Expert Opinion on Therapeutic Targets
Cited by 158

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: ATRX is a chromatin remodeling protein whose main function is the deposition of the histone variant H3.3. ATRX mutations are widely distributed in glioma, and correlate with alternative lengthening of telomeres (ALT) development, but they also affect other cellular functions related to epigenetic regulation. Areas covered: We discuss the main molecular characteristics of ATRX, from its various functions in normal development to the effects of its loss in ATRX syndrome patients and animal models. We focus on the salient consequences of ATRX mutations in cancer, from a clinical to a molecular point of view, focusing on both adult and pediatric glioma. Finally, we will discuss the therapeutic opportunities future research perspectives. Expert opinion: ATRX is a major component of various essential cellular pathways, exceeding its functions as a histone chaperone (e.g. DNA replication and repair, chromatin higher-order structure regulation, gene transcriptional regulation, etc.). However, it is unclear how the loss of these functions in ATRX-null cancer cells affects cancer development and progression. We anticipate new treatments and clinical approaches will emerge for glioma and other cancer types as mechanistic and molecular studies on ATRX are only just beginning to reveal the many critical functions of this protein in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14728222.2018.1487953

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 158

Metadata

Authors
Haase, S., Garcia-Fabiani, M. B., Carney, S., Altshuler, D., Núñez, F. J., Méndez, F. M., Núñez, F., Lowenstein, P. R., & Castro, M. G.
Venue
Expert Opinion on Therapeutic Targets
Published
2018-06-20
Volume
22
Issue
7
Pages
599-613
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2808298958
Cited by
158
References
20
FWCI
5.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant ATRX: uncovering a new therapeutic target for glioma. https://app.cochat.ai/papers/10.1080/14728222.2018.1487953
The paper
Haase, S., Garcia-Fabiani, M. B., Carney, S., Altshuler, D., Núñez, F. J., Méndez, F. M., Núñez, F., Lowenstein, P. R., & Castro, M. G. (2018). Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1487953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.